ProCE Banner Activity

CE

Transitioning to Ready-to-Administer IV Medications: Can it be Both Safe and Affordable?

Video

Watch this on-demand webcast of a live webinar to review how to transition to Ready-to-Administer IV Medications

Pharmacy Technicians: 1.00 contact hour (0.1 CEUs)

Pharmacists: 1.00 contact hour (0.1 CEUs)

Released: March 10, 2023

Expiration: March 09, 2025

Share

Faculty

Christopher Fortier

Christopher Fortier, PharmD, FASHP

Chief Pharmacy Officer
Department of Pharmacy
Massachusetts General Hospital
Boston, Massachusetts

Matthew Grissinger

Matthew Grissinger, RPh, FISMP, FASCP

Director, Education
Institute for Safe Medication Practices
Plymouth Meeting, Pennsylvania

John B. Hertig

John B. Hertig, PharmD, MS

Associate Professor and Chair
Department of Pharmacy Practice
Butler University
Indianapolis, Indiana

Provided by

ProCE Banner

Supporters

 Supported by an educational grant from

Fresenius Kabi

Partners

Institute for Safe Medication Practices (ISMP)

ProCE Banner

Target Audience

The target audience for this activity is pharmacists and pharmacy technicians

Learning Objectives

After completing this activity, participants should be better able to:

  • Describe the risks associated with the preparation and administration of IV medications that are manipulated at the bedside.

  • Compare studies evaluating the cost and safety comparisons between manufacturer-prepared prefilled ready-to-administer (RTA) products versus traditional vial-and-syringe products.

  • Describe an organization’s perspective of the financial savings and improved safety from transitioning from traditional vial-and-syringe medications to manufacturer-prepared prefilled ready-to-administer (RTA) products.

Disclosure

ProCE, LLC requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to ProCE policy. ProCE is committed to providing its learning with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of ineligible company.

The faculty reported the following relevant financial relationships to products or devices they have with ineligible companies related to the content of this educational activity.

Matthew Grissinger, RPh, FISMP, FASCP has no relevant financial relationships to disclose.

John B. Hertig, PharmD, MS, CPPS, FASHP, FFIP: consultant/advisor/speaker: Fresenius Kabi

Christopher R. Fortier, PharmD, FASHP has no relevant financial relationship to disclose.

The planners and content peer reviewers from ProCE, LLC and the Institute for Safe Medication Practices (ISMP), do not have any relevant financial relationships to disclose.

Format

This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Learners have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by healthcare professionals without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities

Accreditation

Pharmacists & Pharmacy Technicians 

This activity is jointly provided by ProCE, LLC and the Institute for Safe Medication Practices (ISMP). ProCE, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-9999-22-212-H05-P/T has been assigned to this home study knowledge-based activity. This activity is approved for 1.0 contact hours (0.10 CEU) in states that recognize ACPE providers. The activity is provided at no cost to participants. Completion of the evaluation and the post-test with a score of 65% or higher are required to receive CE credit. No partial credit will be given. Statements of completion will be issued online at www.ProCE.com, and proof of completion will be posted in NABP CPE Monitor profiles.